Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2022-10-11 Major Shareholding Noti…
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership (including stock option exercises and collateral agreements), and the purpose of holding (management influence) for ABL Bio. This document type is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-10-11 Korean
투자판단관련주요경영사항(이중항체 파킨슨병 치료제 ABL301의 미국 FDA 제1상 임상시험계획 (IND) 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from ABL Bio regarding the submission of an Investigational New Drug (IND) application to the US FDA for a Parkinson's disease treatment (ABL301). This is a specific corporate disclosure regarding material business developments (clinical trial progress). Since it does not fit into specific categories like financial reports, dividends, or board changes, and is a formal regulatory disclosure of a material event, it falls under the RNS (Regulatory Filings) category.
2022-10-04 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a 'Correction Report' (정정신고). It details changes to previously reported stock option grants due to employee resignations and adjustments in the number of shares. This type of disclosure regarding capital structure and equity-based compensation is classified under Regulatory Filings (RNS) as it is a specific corporate disclosure required by the Korea Exchange/Financial Services Commission that does not fit into the other specialized categories like Director's Dealing or Share Issue.
2022-09-30 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a correction filing ('정정신고'). It details changes to stock option grants, including the number of shares and the list of recipients. In the context of Korean financial regulatory filings (DART), this type of disclosure regarding stock options and capital changes falls under general regulatory filings as it does not fit into specific categories like M&A or Dividend announcements.
2022-09-30 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to employees and executives, including the number of shares, exercise price, and vesting conditions. In the context of Korean corporate filings (DART), this is a specific regulatory disclosure regarding capital changes and equity-based compensation. Since it does not fit into the specific categories of 'Director's Dealing' (which usually refers to personal trades) or 'Share Issue' (which refers to the issuance of shares themselves), and it is a mandatory regulatory disclosure, it is best classified as a Regulatory Filing (RNS).
2022-09-28 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Services Commission and Korea Exchange. It details changes in share ownership by major shareholders and special related parties, including specific transaction dates, methods (e.g., gift/donation), and share counts. This type of filing is a standard regulatory requirement for significant ownership changes, which falls under the 'Major Shareholding Notification' category.
2022-09-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.